CA3171330A1 - Methods for treating tauopathy - Google Patents
Methods for treating tauopathyInfo
- Publication number
- CA3171330A1 CA3171330A1 CA3171330A CA3171330A CA3171330A1 CA 3171330 A1 CA3171330 A1 CA 3171330A1 CA 3171330 A CA3171330 A CA 3171330A CA 3171330 A CA3171330 A CA 3171330A CA 3171330 A1 CA3171330 A1 CA 3171330A1
- Authority
- CA
- Canada
- Prior art keywords
- deuterated
- optionally substituted
- ester
- acid
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062976958P | 2020-02-14 | 2020-02-14 | |
| US62/976,958 | 2020-02-14 | ||
| PCT/US2021/017981 WO2021163580A1 (en) | 2020-02-14 | 2021-02-12 | Methods for treating tauopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3171330A1 true CA3171330A1 (en) | 2021-08-19 |
Family
ID=77273602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3171330A Pending CA3171330A1 (en) | 2020-02-14 | 2021-02-12 | Methods for treating tauopathy |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20210251933A1 (https=) |
| EP (1) | EP4103169A4 (https=) |
| JP (2) | JP2023513901A (https=) |
| KR (1) | KR20220140808A (https=) |
| CN (1) | CN116507325A (https=) |
| AU (1) | AU2021220981A1 (https=) |
| CA (1) | CA3171330A1 (https=) |
| IL (1) | IL295512A (https=) |
| WO (1) | WO2021163580A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11510889B2 (en) | 2021-02-05 | 2022-11-29 | Retrotope, Inc. | Methods for inhibiting the progression of neurodegenerative diseases |
| US12109194B2 (en) | 2021-02-05 | 2024-10-08 | Biojiva Llc | Synergistic combination therapy for treating ALS |
| WO2022170134A2 (en) * | 2021-02-05 | 2022-08-11 | Retrotope, Inc. | Dosing protocols for administering deuterated arachidonic acid or a prodrug thereof |
| US11491130B2 (en) * | 2021-02-05 | 2022-11-08 | Retrotope, Inc. | Methods of treating amyotrophic lateral sclerosis |
| KR20240055796A (ko) * | 2021-09-03 | 2024-04-29 | 바이오지바 엘엘씨 | 중수소화 pufa를 이용한 세포 기능장애 및 세포 사멸의 억제를 위한 방법, 시스템 및 조성물 |
| IL313592A (en) * | 2021-12-21 | 2024-08-01 | Biojiva Llc | Methods and preparations for the treatment of inflammatory disease |
| WO2023192406A2 (en) * | 2022-03-30 | 2023-10-05 | Retrotope, Inc. | Prophylactic methods for treating als |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10052299B2 (en) * | 2009-10-30 | 2018-08-21 | Retrotope, Inc. | Alleviating oxidative stress disorders with PUFA derivatives |
| JP6106157B2 (ja) * | 2011-04-26 | 2017-03-29 | レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． | 神経変性障害および筋疾患に関与するｐｕｆａ |
| WO2012148930A2 (en) * | 2011-04-26 | 2012-11-01 | Retrotope, Inc. | Oxidative retinal diseases |
| CN110167546A (zh) * | 2016-11-17 | 2019-08-23 | 乐巢拓普有限公司 | 同位素修饰的组分及其治疗用途 |
| EP3461479B1 (en) * | 2017-09-27 | 2021-06-16 | Julie Blivet | Nutraceutical and pharmaceutical compositions, and uses thereof for preserving cognitive functions |
| JP2021527648A (ja) * | 2018-06-15 | 2021-10-14 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | 後細胞シグナル伝達因子の調節による免疫活性の低減 |
-
2021
- 2021-02-12 CA CA3171330A patent/CA3171330A1/en active Pending
- 2021-02-12 AU AU2021220981A patent/AU2021220981A1/en active Pending
- 2021-02-12 US US17/175,397 patent/US20210251933A1/en not_active Abandoned
- 2021-02-12 WO PCT/US2021/017981 patent/WO2021163580A1/en not_active Ceased
- 2021-02-12 CN CN202180028457.1A patent/CN116507325A/zh active Pending
- 2021-02-12 KR KR1020227031617A patent/KR20220140808A/ko active Pending
- 2021-02-12 IL IL295512A patent/IL295512A/en unknown
- 2021-02-12 EP EP21753302.5A patent/EP4103169A4/en active Pending
- 2021-02-12 JP JP2022548978A patent/JP2023513901A/ja active Pending
-
2024
- 2024-07-09 US US18/767,538 patent/US20250177339A1/en active Pending
-
2025
- 2025-11-25 JP JP2025202414A patent/JP2026035680A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021163580A1 (en) | 2021-08-19 |
| US20250177339A1 (en) | 2025-06-05 |
| CN116507325A (zh) | 2023-07-28 |
| US20210251933A1 (en) | 2021-08-19 |
| JP2023513901A (ja) | 2023-04-04 |
| JP2026035680A (ja) | 2026-03-04 |
| EP4103169A1 (en) | 2022-12-21 |
| IL295512A (en) | 2022-10-01 |
| AU2021220981A1 (en) | 2022-09-22 |
| KR20220140808A (ko) | 2022-10-18 |
| EP4103169A4 (en) | 2024-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250177339A1 (en) | Methods for Treating Tauopathy | |
| US12030863B2 (en) | Prodrugs of urolithins and uses thereof | |
| Besouw et al. | Cysteamine: an old drug with new potential | |
| US20250215026A1 (en) | Deuterated Compounds, Compositions and Uses | |
| ES2812800T3 (es) | Nuevos usos terapéuticos de derivados de la bencilidenguanidina para el tratamiento de proteopatías | |
| JP6313479B2 (ja) | 有機セレン化合物の組成物およびその使用方法 | |
| US20040053989A1 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
| US12251373B2 (en) | Compounds and methods of treating retinal degeneration | |
| US11564924B2 (en) | Pharmaceutical composition formed by combining pyridoxamine compound and thiamine compound | |
| ES2973215T3 (es) | Agente terapéutico para la esclerosis lateral amiotrófica y composición para el tratamiento | |
| RS57624B1 (sr) | Nova sukcinatna jedinjenja koja prodiru u ćelije | |
| WO2008060332A2 (en) | Methods for treating or reducing muscle fatigue | |
| WO2023023397A1 (en) | Methods for inhibiting the progression of neurodegenerative diseases | |
| ES2959243T3 (es) | Nuevo tratamiento de enfermedades mitocondriales | |
| WO2017168137A1 (en) | Pyrimidobenzimidazoles for use in the treatment and prevention of neurodegenerative disorders | |
| JP2006516629A (ja) | 置換キノリンおよび置換ジフェニルスルホンを含有する組成物および方法 | |
| EP2522394B1 (en) | Substituted phosphonates and their use decreasing amyloid aggregates | |
| ES2989515T3 (es) | Fármaco profiláctico o terapéutico para enfermedades neurodegenerativas | |
| US20230165824A1 (en) | METHODS, SYSTEMS AND COMPOSITIONS FOR INHIBITION OF CELLULAR DYSFUNCTION AND CELL DEATH WITH DEUTERATED PUFAs | |
| JP7598195B2 (ja) | 肥満及び関連する障害の予防及び治療のための化合物 | |
| WO2016130908A1 (en) | Therapeutic polysaccharide midi-gagr and related materials and methods | |
| US20220249423A1 (en) | Methods for inhibiting the progression of neurodegenerative diseases | |
| Tan et al. | Lithium co-crystals and an additional neuropsychiatric agent for treatment of neuropsychiatric disorders | |
| HK40023979A (en) | Novel treatment of mitochondrial diseases | |
| HK40023979B (en) | Novel treatment of mitochondrial diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250203 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250203 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250203 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250204 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250204 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250305 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250508 |